# Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

> **NCT03471364** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 58 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** Ketoconazole
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03471364
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-09-15
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471364, "Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03471364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*